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Many advances have been made in the area of pe-diatric clinical pharmacology,1-3 yet a paucity of
information to guide rational prescribing in children
and newborns remains. This is a problem faced by
practitioners in the United States as well as around the
world, leading to reliance on suboptimal prescribing
data placing newborns and children at risk of high rates
of adverse events.4-7 A 1994 study found that there was
a substantial lack of epidemiological studies related to
drug utilization in children, relegating them to the sta-
tus of “methodologic orphans.”8 A current search of lit-
erature in the area of pediatric pharmacoepidemiology
indicates that the problem continues to persist, with
very few studies being published in this field.
This issue is all the more important in the neonatal
population. Newborns who are products of high-risk
pregnancies, premature infants, or those with both
risk factors are at greater risk for medication exposure.
Published data, albeit scarce, show that the number of
drugs administered varies inversely with the gesta-
tional age and/or birthweight of the infant.8-12 Fetal
maturity also plays a role in determining the pharma-
cokinetics of drugs. This is due to developmental fac-
tors affecting (1) drug absorption (in the case of orally
administered drugs); (2) drug distribution such as body
compartment sizes/total body water content, protein
binding, hemodynamic factors, and so on; and (3) drug
metabolism/clearance (either renal or hepatic) due to
ontogenetic differences in blood flow through the me-
tabolizing organs as well as drug-metabolizing en-
zyme activity.2,3,13 Thus, newborn infants are more
prone to drug adverse events when compared to
adults.14 Exposure to multiple drugs is also known to
be a factor leading to increased incidence of adverse
events in neonates.15,16
Published data show that the average number of
drugs administered per infant in the neonatal intensive
care unit (NICU) had progressively increased over the
years. A Canadian study done in the 1970s showed an
increase in mean drug per neonate from 3.4 to 6.2 over a
3-year time period.17 The mean number of drugs used
in newborns in the NICU in an Australian study pub-
lished in 1989 was 8.6 ± 0.9.18 The median number of
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The objective of this study was to determine drug use in new-
borns at an inborn tertiary care neonatal intensive care unit,
serving a predominantly African American population, to
identify educational/research priorities in neonatal drug
therapy. Data on demographics and exposure rates to all
drugs from 6839 neonates born between January 1997 and
June 2004 were analyzed. Number of drugs used was corre-
lated with race, gender, gestational age, birthweight, and sur-
vival status. The contribution of these factors to mean drug
use was predicted by multivariate regression analysis. In this
population of 80% African Americans, mean drug use was
3.6/infant, with the highest use in the 24- to 27-week gesta-
tional age group (11.7/infant). Ampicillin and cefotaxime had
the highest exposure rates. Premature infants had high use of
surfactant, pressor agents, and diuretics. Caucasians, males,
gestational age <28 weeks, and birthweight <1000 g were
the risk factors for higher drug exposure. Future research/
education must emphasize these therapeutic areas with pri-
ority assigned to low-birthweight infants.
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drugs used per infant in a US population published
during this same time period was 8/infant.10 In most of
these studies, antibiotics were the one category of
drugs that had maximum utilization rates. There are no
data available on the prevalence of antifungal use in
this population, despite the recognition of the increas-
ing incidence of fungal infections and subsequent
antifungal therapy in newborns.19-23
Changes in neonatal drug therapy, including the in-
troduction of many new drugs, have occurred over the
past decade. There have been few studies documenting
these changes, and an ongoing review of drug utiliza-
tion patterns in sick newborns was warranted to assign
research and educational priorities in neonatal phar-
macology. Our study objectives were to (1) determine
the actual drug utilization patterns in neonates, (2)
identify the most commonly used drugs in neonates
and the actual frequency of their use, and (3) identify
the areas in neonatal pharmacology that are in need of
further research, as reflected by our experience at a
single, tertiary care neonatal intensive care unit.
MATERIALS AND METHODS
Study Design and Population
This study was approved by the Wayne State Univer-
sity Human Investigations Committee and was a retro-
spective data analysis of the drug utilization patterns of
6839 neonates treated at Hutzel Women’s Hospital
(HWH) in Detroit between January 1997 and June 2004.
The neonates included in this study had to be born be-
tween January 1997 and June 2004, with postnatal age
≤28 days at admission, and required the administration
of at least 1 drug. Both male and female infants of any
race admitted to the Hutzel NICU or Progressive Care
Nursery (PCN—a step-down unit of NICU) were in-
cluded. HWH is a large teaching hospital that serves as
the obstetrical site for a predominantly African Ameri-
can urban population, and the NICU is a level III unit
that provides care for an almost exclusively inborn
population.
Data Sources
Study data were obtained from a review of the neonatal
database (NEOSYSTEM), a network-based computer
system designed and in use at HWH since January
1997. The purpose of this system is to generate admis-
sion notes, daily progress notes, discharge summaries,
and monthly statistics for neonates admitted to the
NICU, PCN, and normal newborn units. PC (personal
computer) clients connected to the main server are lo-
cated at these 3 units. Residents, staff physicians, and
nursing staff who provide care for the infants are re-
sponsible for data entry. FoxPro software was used to
retrieve data.
Study Endpoints and Analysis
Data on gender, race, gestational age, birthweight,
length of hospital stay (number of days from date of
birth until date of discharge), survival status at dis-
charge, and all pharmacological agents used were col-
lected and analyzed. Data regarding the following were
not collected: blood and blood products (except fresh
frozen plasma), total parenteral nutrition, oxygen ad-
ministration, vitamin K prophylaxis, erythromycin
ophthalmic prophylaxis, routine cord care, and any
vaccinations received. We also did not assess the utili-
zation rates of routine parenteral fluids. Normal saline
was included in our analysis only when it was given for
a specific indication of hypotension.
Drugs used were classified into 10 categories: antibi-
otics, diuretics, vitamins/minerals/nutritionals, bio-
logicals, cardiovascular agents, respiratory agents,
ophthalmic agents, neurological agents, hormones,
and miscellaneous agents. The total number of drugs
administered to each neonate was calculated and tabu-
lated, and exposure rates to all drugs used were
examined.
Race, gender, gestational age, birthweight, and dis-
charge status were then correlated with the number of
drugs used with t tests, Pearson correlation analysis, or
analysis of variance. Multiple regression analysis was
also performed on the number of drugs used with race,
gender, discharge status, birthweight, and gestational
age as predictors.
RESULTS
As shown in Table I, ethnicity was predominantly Afri-
can American, with Caucasians, Hispanics, and other
minorities represented in smaller numbers. Of these,
46% were females and 54% were males. Mean length
of stay was 15 ± 24 (SD) days, mean gestational age was
35 ± 5 (SD) weeks, and mean birth weight was 2498 ±
1000 (SD) grams. Approximately 97% of babies were
alive at the time of discharge.
Mean drug use was 3.6 ± 3.9 (SD) per infant when all
infants were included, although the average number of
drugs administered varied depending on gestational
age and birthweight. The highest drug use was in the
24- to 27-week gestational age infants at 11.8/infant (Fig.
1), followed by the <23-week category at 9.9/infant.
When based on birthweight, the highest mean drug use
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was in the 501- to 750-g birthweight category at 12.3/
infant (Fig. 2), followed by the 751- to 1000-g infant at
11.1/infant. Infants with birthweight <500 g had mean
drug use of 8.8/infant.
The top 15 drugs used in all infants are listed in Ta-
ble II. The antibiotics ampicillin and cefotaxime were
the 2 most widely used drugs, with rates of exposure far
outstripping exposure to any other drug. The third
most widely used drug was surfactant (Survanta),
which was probably a reflection of the high percentage
of premature infants (52%, Table I). Exposure to the
next 13 drugs on the list was less than a quarter of that
of the top 2 drugs.
A subgroup analysis by gestational age revealed an
interesting but not unexpected progression in the use
of certain drugs (Table III). All infants of gestational age
≤23 weeks were exposed to ampicillin, cefotaxime, and
surfactant. Exposure to these drugs decreased in the 24-
to 27-week infants and continued to drop as the gesta-
tional age increased. But in the case of vancomycin,
iron, diuretics, dexamethasone, indomethacin, and re-
spiratory agents other than surfactant, exposure rates
peaked in the 24- to 27-week infants and subsequently
decreased. In fact, other than the antibiotics ampicillin
and cefotaxime, which did not have a significant de-
crease in exposure across gestational age groups, all
other drugs had a marked decrease in exposures
beyond the 27-week age group.
Antifungal exposure (including amphotericin
deoxycholate, liposomal amphotericin, fluconazole,
flucytosine, and nystatin) was 2.3% in all infants and
was highest in the <23-week infants at 20.6%, followed
by 24- to 27-week infants at 19%. In the 28- to 31-week
infants, it decreased drastically to 5.6% and was <1%
for infants >32 weeks. Most of this was contributed to
by amphotericin (both liposomal and deoxycholate),
with exposure rates being 17.7%, 18.3%, 5%, and <1%
in infants <23 weeks, 24 to 27 weeks, 28 to 31 weeks,
and >32 weeks, respectively.
A multivariate analysis of the data was performed to
identify factors associated with higher number of drug
use (Table III). Caucasian ethnicity, male gender, a ges-
tational weight of <28 weeks, and weight <1000 g were
associated with higher drug use, whereas early death
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Mean birthweight 2498 (SD = 1000 g)
Mean gestational age 35 (SD = 5 weeks)
Percentage of infants in each
gestational age category
≤ 23 weeks 0.5
24 to ≤ 27 weeks 8
28 to ≤ 31 weeks 11.7
32 to ≤ 37 weeks 31.8
≥ 38 weeks 48
Mean length of staya 15 (SD = 24 days)
Survival rate,b % 97
a. Mean length of stay: number of days from date of birth until date of
discharge.
b. Survival rate: whether discharged alive or not. If the patient expired,


































































































Figure 2. Mean drug use by birthweight.
(<7 days) was associated with lower drug use. Al-
though gestational age and birthweight are known to be
correlated, a regression model including both factors
yielded a higher R2 (0.502) than models including only
1 of the 2 factors (0.445 and 0.454). Thus, we chose to
include both factors in our final model to maximize the
predictive power.
DISCUSSION
Recent advances in prenatal care have resulted in an
increase in drug exposure rates in pregnant mothers,
causing infants to be exposed to a multitude of different
drugs, even when in utero.24,25 Advances in medical
technology have also resulted in improved survival
rates in both term and preterm infants, including high-
risk and low-birthweight infants.26 As a result of these
changes in the medical management of the newborn,
drug exposure patterns in infants have also changed.
Although there is a general appreciation that neonates,
especially preterm neonates, have high drug utilization
rates, a systematic evaluation is needed to prioritize ar-
eas in need of further pharmacotherapeutic research.
This will also help document changes in the trend of
medication use, define the groups of infants that are at
higher risk for adverse events, and provide necessary
information to estimate the costs and benefits of
current NICU care.
In this study, we examined an urban, medically
underserved population with a high incidence of high-
risk pregnancies. The NICU/PCN studied is a desig-
nated level III center and primarily admits infants de-
livered by the HWH obstetrical service. We excluded
data on the use of vitamin K prophylaxis, erythromycin
ophthalmic prophylaxis, and routine cord care as these
are administered to all infants born at HWH, and data
on these would not have contributed any significant in-
formation. Data regarding parenteral solutions other
than normal saline given for an indication of
hypotension, blood and blood products except fresh
frozen plasma, total parenteral nutrition, oxygen ad-
ministration, and any vaccinations received were also
not collected because of their extensive use.
The population characteristics of our patients dif-
fered from those of previous studies in that it consisted
of a majority of African Americans, a historically
underserved community. The mean gestational age
and birthweight were also higher than those of previ-
ous studies. Mean drug use in our study was lower than
we expected, and when compared to previous studies,
there was no increase in mean drug use.11,18 This could
be explained by the fact that (1) the patients in our
study had greater mean gestational age and
birthweight, (2) our NICU cares for patients with lesser
disease acuity, and (3) previous studies included infor-
mation regarding some of the drugs that we excluded
due to the ubiquity of their use. Comparison with pre-
vious studies was thus difficult due to these reasons as
well as the temporal distance involved.
Very premature infants are known to have high rates
of medical complications necessitating prolonged
NICU stay periods, which ultimately result in higher
mean drug use and exposure rates. Our results were
consistent with this, with mean drug use being maxi-
mal in the 24- to 27-week infants, with the ≤23-week in-
fants a close second. It is also interesting to note that
similar to previous studies, in our study also, ethnicity
and gender played a role in determining survival out-
comes in neonates, with African Americans and fe-
males having better survival outcomes (data not
shown).26 It is known that Caucasian neonates and
male neonates have higher mortality rates.26,27 Al-
though it is not possible to derive any firm conclusions,
our observed increase in drug exposure in these groups
could be a reflection of an increased morbidity in these
groups.
The high rate of antibiotic exposure in our study is
similar to studies published in the past9 and is probably
due to the standard practice of administering antibiot-
ics pending bacterial culture results in sick neonates
and is not a true reflection of the incidence of bacterial
infection.27 Vancomycin exposure was also surpris-
ingly high in our study when compared to the actual in-
cidence of methicillin-resistant organisms in the NICU
452 • J Clin Pharmacol 2006;46:449-455
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Table II Exposure Rates for the
Top 15 Drugs: All Infants




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































as reported in literature.28-30 Exposure to amphotericin
paralleled the incidence of neonatal Candida infection
reported in literature.21-23 It was not surprising that
surfactant and other respiratory agents, vasopressors,
and diuretics had high exposure rates, especially in
the very premature infant, although the high expo-
sure to iron supplements, sodium supplements,
metoclopramide, and indomethacin was unexpected.
Pressors had high exposure rates in the very premature
infant, although these drugs have not been well studied
in this population.31 Diuretic use is also high in the pre-
mature infant, although long-term outcomes of di-
uretic therapy are still unknown.32 Individual agents
used have also changed, with drugs such as
kanamycin, tolazoline, having disappeared from the
formulary and newer drugs such as surfactant,
ceftazidime, cefepime, making their presence felt.
There have been very few studies documenting the
observed changes and comparisons across gestational
age groups, making this study pertinent. Such docu-
mentation is important, as neonates are more prone to
adverse events/potential adverse events.33 This may be
due to polypharmacy, which is known to increase the
risk of adverse events;34,35 lack of proper drug evalua-
tion trials; and, in the case of premature/low-
birthweight infants, immaturity of drug-metabolizing
pathways. It also helps define the extent of expenditure
due to pharmacotherapy that is driven by the different
gestational ages.
A strength of our study is that it is the largest of its
kind (n = 6839), thus increasing the power and validity
of the conclusions drawn. A limitation was that quality
of data collection was dependent on the personnel en-
tering the data. Because data were entered by different
individuals (residents, fellows, nursing staff), there
may have been some data entry deficiencies, leading to
uneven reporting of drug use. This may have resulted
in a systematic underestimation of drugs administered.
Data regarding analgesic use may have been
underrepresented because they are given on an as-
needed basis and may not always be entered into the
system. In summary, it is clear that the trend toward
polypharmacy continues in neonates in the NICU, and
drug exposure continues to be dictated by gestational
age and/or birthweight. There still remain many areas
in neonatal pharmacology that are in need of further
studies, especially with regard to the use of antibiotics,
pressor agents, and diuretics in the premature infant.
This study was supported by the Sarnaik Pediatric Research for
Residents and Fellows Endowment, and the Children’s Research
Center of Michigan.
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